Supplementary material The supplementary material for this article can be found at Acknowledgements The authors gratefully acknowledge all the members involved in the project
Shorter periods may show initial response but do not capture full potential
After 48 h of incubation, both liposomal formulations maintained cell viability above 80% in each cell line, indicating good biocompatibility (Fig
Key Points Semaglutide is not FDA-approved to treat PCOS Some studies, however, show that semaglutide helped women with PCOS lose weight Weight loss often helps PCOS symptoms by reducing insulin resistance and hormonal imbalances Proper nutrition plays a key role in managing PCOS PCOS carries serious long-term health consequences, including an increased risk of diabetes, heart disease, and fertility challenges
The importance of lifestyle alongside medication Semaglutide is a tool, not a complete solution
The demographic skewed toward women aged 35 to 60, and marketing increasingly targeted perimenopausal women with language about "personalized" and "gentle" dosing